Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/34c95a65-3897-434d-a9d2-a51fdf5f7f46/

HBIO

Harvard Bioscience Inc
Chart
$6.20
Latest Week 2026-06-05
HealthcareMedical Instruments & SuppliesNANO
Snapshot 2026-06-07 · 0.0w · Fresh
0.56
OS Score
51.0%
Value
51.0%
Quality
51.0%
Momentum
4/9
F-Score
0.510
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
Yes
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
51.0%ile
P/S
0.3×
P/B
2.8×
FCF Yield
0.071
EBITDA/EV
0.029
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
49.00000000
/100 — 1=cheapest
VC2 (Trending Value)
49.00000000
/100
VC3 (Buyback)
49.00000000
/100
FCF yield of 7.1% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
51.0%ile
ROE
-0.974
ROA
-0.126
Net Margin
-0.114
Op Margin
-0.030
GPA
0.626
D/E
6.76
Current
1.99
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
-0.064
Stability
2.002
lower=better
Accruals
-0.162
lower=better
5yr Consist
No
Highly leveraged with D/E of 6.76 — returns are being amplified by debt.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
51.0%ile
6M Return
-18.2%
12M Return
51.5%
12-1 Mom
68.6%
Risk-Adj
0.76
Vol 252d
90.4%
Vol 60d
200.6%
↑ Expanding
Max DD 12M
-43.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 69% is very strong — a clear uptrend. Near-term vol (201%) is expanding vs long-term (90%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.56
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
33.7%
Sector Quality %ile
36.1%
P/B z-score
-0.19
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Volatility Expanding
60-day vol (201%) significantly exceeds 252-day (90%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
52.1% avg (5 factors)
Quality
D
33.1% avg (8 factors)
Momentum
B
62.3% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.560—0—
Value %ile0.510—0—
Quality %ile0.510—0—
Momentum %ile0.510—0—
F-Score4.000—1—
Confidence0.879—1—
Volatility0.904—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
0.32
Price / Book
2.76
Price / Cash Flow
9.80
FCF Yield
7.1%
EBITDA / EV
2.9%
Sales Yield (1/P·S)
1.4652
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-97.4%
Return on Assets
-12.6%
Net Margin
-11.4%
Operating Margin
-3.0%
Gross Profit / Assets
Novy-Marx GPA
62.6%
Debt / Equity
6.76
Current Ratio
1.99
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.162
MomentumPrice trend strength over different horizons
6M Return
-18.2%
12M Return
51.5%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
68.6%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.76
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
-6.4%
Earnings Stability (CV)
Lower = more stable
2.002
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
49
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
49
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
49
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
Yes
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity